Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Rivero Juarez, Antonio ^a   Gonzalez, Rafael ^a   Camacho, Angela ^a   Manzanares Martin, Barbara ^a   Caruz, Antonio ^b   Martinez Peinado, Antonio ^a   Torre Cisneros, Julian ^a   Pineda, Juan A ^c   Peña, José ^a   Rivero, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; INTERLEUKIN 28; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HLA B GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERLEUKIN 28 GENE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1 GENE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHARMACOLOGICAL PARAMETERS; RAPID VIROLOGICAL RESPONSE; SUSTAINED VIROLOGICAL RESPONSE; VIRAL CLEARANCE;

ADULT; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, KIR3DS1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84876177786     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061992     Document Type: Article

References (38)

1. Pineda JA, Caruz A, Rivero A, Neukan K, Salas I, et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 51: 788-95.
2. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461: 399-401.
3. Rivero-Juarez A, Camacho A, Perez-Camacho I, Neukam K, Caruz A, et al. (2012) Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother 67: 202-5.
4. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, et al. (2010) Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-9.
5. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic Hepatitis C. Hepatology 52: 1888-1896.
6. Naggie S, Osinusi A, Katsounas A, Lempicki R, Hermann E, et al. (2012) Dysregulation of innate immunity in HCV genotype 1 IL28B unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 56: 444-54.
7. Rivero-Juarez A, Camacho A, Caruz A, Neukam K, Gonzalez R, et al. (2012) LDLr Genotype Modifies the Impact of IL28B on HCV Viral Kinetics after the First Weeks of Treatment with PEG-IFN/RBV in HIV/HCV Patients. AIDS 15: 1009-15.
8. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, et al. (2012) Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 25: 1415-20.
9. Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, et al. (2011) Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV medicine. 12: 487-93.
10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
11. Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, et al. (2012) Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology 56: 841-9.
12. Edlich B, Ahlenstiel G, Azpiroz AZ, Stoltzfus J, Noureddin M, et al. (2012) Early Changes in Interferon Signaling Define Natural Killer Cell Response and Refractoriness to Interferon-Based Therapy of Hepatitis C Patients. Hepatology 55: 39-48.
13. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, et al. (2011) Early Changes in Natural Killer Cell Function Indicate Virologic Response to Interferon Therapy for Hepatitis C. Gastroenterology 141: 1231-1239.
14. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP, (1999) Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annual Review of Immunology 17: 189-220.
15. Borrego F, Kabat J, Kim DK, Lieto L, Maasho K, et al. (2002) Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 38: 637-60.
16. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, et al. (2011) IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 8: e1001092.
17. Golden-Mason L, Bambha KM, Cheng L, Howell CD, Taylor MW, et al. (2012) Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology 54: 1559-1569.
18. Lopez-Vazquez A, Rodrigo L, Martinez-Borra J, Pérez R, Rodríguez M, et al. (2005) Protective Effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 192: 162-165.
19. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL, (2007) Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 178: 647-651.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, Management and Treatment of Hepatitis C: An update. AASLD Practice Guidelines. Hepatology 49: 1335-1374.
21. Gomez-Lozano N, Vilches C, (2002) Genotyping of Human Killer-Cell Immunoglobulin-Like Receptor Genes by Polymerase Chain Reaction with Sequence-Specific Primers: An Update. Tissue Antigens 59: 184-193.
22. Gillespie GM, Bashirova A, Dong T, McVicar DW, Rowland-Jones SL, Carrington M, (2007) Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res Hum Retroviruses 23: 451-5.
23. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874.
24. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha NI, et al. (2010) Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51: 1168-75.
25. Vidal-Castineira JR, Lopez-Vazquez A, Diaz-Pena R, Alonso-Arias R, Martinez-Borra J, et al. (2010) Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84: 475-81.
26. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, et al. (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31: 429-34.
27. Foley BA, De Santis D, Van Beelen E, Lathbury LJ, Christiansen FT, et al. (2008) The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patients and donor suitability for haploidentical stem cell transplantations. Blood 112: 435-443.
28. GaudieriS, DeSantis D, McKinnon E, Moore C, Nolan D, et al. (2005) Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 6: 683-90.
29. Barbour JD, Sriram U, Caillier SJ, Levy JA, Hecht FM, et al. (2007) Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 3: e43.
30. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204: 3027-36.
31. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, et al. (2011) HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476: 96-100.
32. Lanier LL, (2005) NK cell recognition. Annu Rev Immunol 23: 225-74.
33. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtype against HIV-1. Nat Genet 39: 733-40.
34. Hofmann WP, Zeuzem S, (2011) A new standard of care for treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8: 257-64.
35. Dieterich D, Soriano V, Sherman K, Girad P-M, Rockstroh J, et al. (2012) Telaprevir in combination with pegylated interferon-α-2a + ribavirin in HCV/HIV-co-infected patients: a 24-week treatment interim analysis [oral abstract 46]. In: Program and abstracts of the 19th Conference on Retroviruses and opportunistic infections (CROI). Seattle,USA. Communication number 93.
36. Sulkowski M, Pol S, Cooper C, Fainboim F, Slim J, et al. (2012) Boceprevir + Pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week 48) interim results [oral abstract 47]. In: Program and abstracts of the 19th Conference on Retroviruses and opportunistic infections (CROI). Seattle,USA. Communication number 94.
37. Seden K, Back D, (2011) Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Current Opinion on HIV and AIDS 6: 514-26.
38. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P, (2010) Viral hepatitis and HIV co-infection. Antiviral Res. 85: 303-315.